|Epigenomics AG -- USA Stock|| |
USD 4.49 0.26 5.47%
Chairman of the Supervisory Board
Mr. Heino von Prondzynski is Chairman of the Supervisory Board of Epigenomics AG since May 2, 2012. He was Member of the Supervisory Board at Epigenomics AG from May 29, 2007 until March 31, 2010. Until December 2005, he headed the Diagnostics Division at F.HoffmannLa Roche AG, Basel. Before that, he held senior positions in the Vaccine business at Chiron Corporationration in Germany, Italy and the Unted States and in the Pharma, Selfmedication and Diagnostic business at Bayer AG in Germany, Austria and Brazil. After retiring from his position as Chief Executive Officer of the Roche Diagnostics division, Mr. von Prondzynski works as Independent Consultant. He serves at the Supervisory Boards of Koninklijke Philips Electronics NV, Qiagen NV and Hospira Inc., among others.
Age: 67 Chairman Since 2012
49 30 243 450 http://www.epigenomics.com
von Prondzynski studied mathematics, geography, and history at the Westfaelische WilhelmsUniversitaet, Muenster, Germany.
The company has return on total asset (ROA)
of (44.29) %
which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (122.69) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.
Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Berlin, and employs 43 people.